ARTICLE | Deals
Lilly steps up in vaccines with three acquisitions: Deals Report
Pharma to obtain Shingrix competitor, clinical S. aureus product, nanoparticle technology and more via trio of takeouts
May 26, 2026 11:26 PM UTC
As Lilly continues to direct some of its massive cash flow toward M&A activity, three of its latest deals are in an area it hadn’t previously prioritized: vaccines.
Eli Lilly and Co. (NYSE:LLY) said Tuesday it will acquire three companies in the vaccine space in agreements whose total value could rise to about $3.8 billion, including milestones...